Novartis Ag (NVS) Change in Intangibles (2009 - 2026)
Novartis Ag (NVS) posted Change in Intangibles of -$461.0 million for Q1 2026, down 12.99% sequentially from -$408.0 million in Q4 2025.
Novartis Ag (NVS) Change in Intangibles (2009 - 2026) Analysis & Trends
Novartis Ag (NVS) has 12 years of Change in Intangibles data on file, last reported at -$461.0 million in Q1 2026.
- Quarterly Change in Intangibles changed N/A year-over-year to -$461.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 billion (changed N/A YoY) and the FY2025 annual result came in at $164.0 million, up 105.0% from the prior year.
- Change in Intangibles eased to -$461.0 million in Q1 2026 per NVS's latest filing, from -$408.0 million in the prior quarter.
- The five-year high for Change in Intangibles was -$192.0 million in Q4 2022, with the low at -$929.0 million in Q1 2024.
- Average Change in Intangibles over 5 years is -$442.8 million, with a median of -$441.5 million recorded in 2023.
- Year-over-year, Change in Intangibles jumped 63.29% in 2023 and sank 320.36% in 2024.
- Novartis Ag's Change in Intangibles stood at -$192.0 million in 2022, then tumbled by 96.35% to -$377.0 million in 2023, then slumped by 51.99% to -$573.0 million in 2024, then increased by 28.8% to -$408.0 million in 2025, then declined by 12.99% to -$461.0 million in 2026.
- Business Quant data shows NVS's Change in Intangibles at -$461.0 million in Q1 2026, -$408.0 million in Q4 2025, and -$477.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -991.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -461.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -461.00 Mn |
| Mar 31, 2026 | -461.00 Mn |
| Dec 31, 2025 | -408.00 Mn |
| Dec 31, 2025 | -408.00 Mn |
| Sep 30, 2025 | -477.00 Mn |
| Sep 30, 2025 | -477.00 Mn |
| Jun 30, 2025 | -227.00 Mn |
| Jun 30, 2025 | -227.00 Mn |
| Dec 31, 2024 | -573.00 Mn |
| Dec 31, 2024 | -573.00 Mn |
| Sep 30, 2024 | -478.00 Mn |
| Sep 30, 2024 | -478.00 Mn |
| Jun 30, 2024 | -468.00 Mn |
| Jun 30, 2024 | -468.00 Mn |
| Mar 31, 2024 | -929.00 Mn |
| Mar 31, 2024 | -929.00 Mn |
| Dec 31, 2023 | -377.00 Mn |
| Dec 31, 2023 | -377.00 Mn |
| Sep 30, 2023 | -422.00 Mn |
| Sep 30, 2023 | -422.00 Mn |